Biology of senescent liver peroxisomes: Role in hepatocellular aging and disease

Environmental Health Perspectives

Volumn 107, Issue 10, 1999, Pages 791-797

  Youssef, Jihan ^a   Badr, Mostafa ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Aging; Peroxisomal disorders; Peroxisome proliferator activated receptors; Peroxisomes

Indexed keywords

AGING; DISORDERS OF PEROXISOMAL FUNCTIONS; HEALTH; LIVER CARCINOGENESIS; LIVER CELL; LIVER DISEASE; PEROXISOME; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0032724260     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.99107791     Document Type: Review

References (96)

1. Dice JF. Cellular and molecular mechanisms of aging. Physiol Rev 73:149-159 (1993).
2. Cuder RG. Longevity is determined by specific genes. In: Testing the Theories of Aging (Adelman RC, Roth GS, eds). Boca Raton, FL:CRC Press, 1982;25-114.
3. Rubin H. Cell aging in vivo and in vitro. Mech Ageing Dev 98:1-35 (1997).
4. Makarides S. Protein synthesis and degradation during aging and senescence. Biol Rev 58:343-422 (1983).
5. Dice JF. Cellular theories of aging as related to the liver. Hepatology 5:508-513 (1985).
6. Tauchi H, Sato T. Hepatic cells of the aged. In: Liver and Aging (Kitani K, ed). Amsterdam:Elsevier, 1978;3-19.
7. Popper H. Aging and the liver. Prog Liver Dis 8:659-683 (1986).
8. Bucher NLR. Regeneration of mammalian liver. Int Rev Cytol 15:245-300 (1963).
9. Schapiro H, Hotta SS. Dutten WE, Klein AW. The effect of aging on rat liver regeneration. Experientia 38:1075-1076 (1982).
10. Wilson P, Franke LM. The effect of age on mitochondrial ultrastructure. Gerontologia 21:81-94 (1975).
11. Herberer GH. A morphometric study of age dependent changes in mitochondrial population of mouse liver and heat. J Gerontol 31:8-12 (1976).
12. Weindruch RH, Cheung MK, Verity MA, Walford RL Modification of mitochondrial respiration by aging and dietary restriction. Mech Ageing Dev 12:375-392 (1980).
13. Schmucker DL, Wang MM. Age-related changes in liver drug metabolism: structure vs. function. Proc Soc Exp Biol Med 165:178-187 (1980).
14. Birnbaum LS. Hepatic drug metabolism in senescent mice. Exp Gerontol 15:259-267 (1980).
15. Rikans LE, Moore DR. Effect of age and sex on allyl alcohol hepatotoxicity in rats: role of liver alcohol and aldehyde dehydrogenase activities. J Pharmacol Exp Ther 243:20-26 (1987).
16. Lazarow P, Fujiki V. Biogenesis of peroxisomes. Annu Rev Cell Biol 1:489-530 (1985).
17. Bentley P, Elcombe C, Grasso P, Stringer D, Wiegand H. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol 31:857-907 (1993).
18. Staubli W, Hess F, Weibel E. Correlated morphometric and biochemical studies on the rat liver cell. II: Effects of phenobarbital on rat hepatocytes. J Cell Biol 42:92-112 (1969).
19. Weibel E, Staubli W, Gangi H, Hess F. Correlated morphometric and biochemical studies on the liver cell. I: Morphometric model, stereologic methods, and normal morphometric data for rat liver. J Cell Biol 42:68-91 (1969).
20. del Rio LA, Sandalio LM, Palma JM. A new cellular function for peroxisomes related to oxygen free radicals. Experientia 46:989-992 (1990).
21. Tolbert N. Metabolic pathways in peroxisomes and glyoxysomes. Annu Rev Biochem 50:133-157 (1981).
22. Van den Bosch H, Schutgens RBH, Wanders RJA, Tager JM. Biochemistry of peroxisomes. Annu Rev Biochem 61:157-197 (1992).
23. Paget G. Experimental studies of the toxicity of atromid with particular reference to fine structural changes in the livers of rodents. J Atheroscler Res 3:729-736 (1963).
24. Youssef J, Badr M. Extraperoxisomal targets of peroxisome proliferates: mitochondrial, microsomal, and cytosolic effects: implication for health and disease. CRC Crit Rev Toxicol 28:1-33 (1998).
25. De La Iglesia F, Lewis J, Buchanan R, Marcus E, McMahon G. Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis 43:19-37 (1982).
26. Eacho P, Foxworthy P, Johnson W, Hoover D, White S. Hepatic peroxisomal changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species. Toxicol Appl Pharmacol 83:430-437 (1986).
27. Desch F, Schladt L, Steinberg P, Thomas H. Concomitant induction of cytosolic epoxide hydrolase and peroxisomal ß-oxidation by hypolipidemic compounds in rat and guinea pig liver. Arch Toxicol 12(suppl):248-255 (1988).
28. Lake B, Evans J, Gray T, Korosi S, North C. Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig and marmoset. Toxicol Appl Pharmacol 99:148-160 (1989).
29. Watanabe T, Horie S, Yamada J, Isaji M, Nishigaki T, Naito J, Suga T. Species differences in the effect of bezafibrate, a hypolipidemic agent, on hepatic peroxisome-associated enzymes. Biochem Pharmacol 38:367-371 (1989).
30. Sakuma M, Yamada J, Suga T. Comparison of the inducing effect of dehydroepiandrosterone on hepatic peroxisome proliferation-associated enzymes in several rodent species. Biochem Pharmacol 43:1269-1273 (1992).
31. Horie S, Ishii H, Suga T. Changes in peroxisomal fatty acid oxidation in the diabetic rat liver. J Biochem 90:1691-1696 (1981).
32. Thomas H, Schladt L, Knehr M, Desch F. Effect of diabetes and starvation on the activity of rat liver epoxide hydrolase, glutathione S-transferase and peroxisomal β-oxidation. Biochem Pharmacol 38:4291-4297 (1989).
33. Fringes B, Reith A. Time-course of peroxisome biogenesis during adaptation to mild hyperthyroidism in rat liver: a morphometric/stereolocic study by electron microscopy. Lab Invest 47:19-26 (1982).
34. Fringes B, Reith A, Riede U. Peroxisome biogenesis in rat liver during adaptation to mild hyperthyroidism: a morphometric/stereologic study by electron microscopy. Ann NY Acad Sci USA 386:514-518 (1982).
35. Levy E, Slusser R, Ruebner B. Hepatic changes produced by a single dose of endotoxin in the mouse. Am J Pathol 52:477-502 (1968).
36. Neat C, Thomassen M, Osmundsen H. Induction of peroxisomal β-oxidation in rat liver by high fat diet. Biochemistry 186:369-371 (1980).
37. Rigatuso JL, Legg PG, Wood RL. Microbody formation in regenerating rat liver. J Histochem Cytochem 18:893-900 (1970).
38. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650 (1990).
39. Tsai M, O'Malley B. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 53:451-486 (1994).
40. Gottlicher M, Widmark E, Li Q, Gustafsson J-A. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 89:4653-4657 (1992).
41. Kliewer S, Forman B, Blumberg B, Ong E, Borgmeyer U, Mangelsdorf D, Umesono K. Evans R. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91:7344-7349 (1334).
42. Tontonoz P, Singer S, Forman B, Sarraf P, Fletcher J, Fletcher C, Brun R, Mueller E, Altoik S, Oppenheim H, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferetor-activated receptors y and the retinoid X receptor. Proc Natl Acad Sci USA 94:237-241 (1997).
43. Berger J, Leibowitz M, Doebber T, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan C, Hayes N, Li Y, et al. Novel peroxisome proliferator-activated receptor (PPAR)γ and PPARδ ligands produce distinct biological effects. J Biol Chem 274:6718-6725 (1999).
44. 4 pathway to inflammation control. Nature 384:39-43 (1996).
45. Forman B, Chen J, Evans R. Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 94:4312-4317 (1997).
46. Wolf G. Fatty acids bind to and activate peroxisome proliferator-activated receptors α and γ. Nutr Rev 56:61-63 (1998).
47. Gustafsson J-A. Fatty acids in control of gene expression. Nutr Rev 56:S20-S21 (1998).
48. Sher T, Yi H, McBride O, Gonzalez F. cDNA cloning, chromosomal mapping and functional characterization of the human peroxisome proliferates activated receptor. Biochemistry 32:5598-5604 (1993).
49. Mukherjee R, Jow L, Noonan D, McDonnell D. Human and rat peroxisome proliferates activated receptor (PPARδ) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Mol Biol 51:157-166 (1934).
50. Greene M, Blumberg B, McBride O, Yi H, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer S. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hemetopoietic cells and chromosomal mapping. Gene Exp 4:281-200 (1995).
51. Su J-L, Simmons C, Wisely B. Ellis B, Winegar D. Monitoring of PPAR alpha protein expression in human tissue by the use of PPAR alpha-specific mab. Hybridoma 17:47-53 (1938).
52. Perichon R, Bourre JM. Peroxisomal β-oxidation activity and catalase activity during development and aging in mouse liver. Biochimie 77:288-293 (1995).
53. Perichon R, Bourre JM. Age-related decrease in liver peroxisomal fatty acid oxidation in control and clofibrate-treated mice. A biochemical study and mechanistic approach. Mech Ageing Dev 87:115-126 (1996).
54. Cattley RC, Marsman DS, Popp JA. Age-related susceptibility to the carcinogenic effect of the peroxisome proliferator WY-14,643 in rat liver. Carcinogenesis 12:469-473 (1991).
55. Huber W, Kraupp-Grasl B, Esterbauer H, Schulte-Harmann R. Role of oxidative stress in age-dependent hepatocarcinogenesis by the peroxisome proliferator nafenopin in the rat. Cancer Res 51:1789-1792 (1991).
56. Beier K, Volkl A, Fahimi H. The impact of aging on enzyme proteins of rat liver peroxisomes-quantitative analysis by immunoblotting and immunoelectron microscopy. Virchows Arch B 63:139-146 (1993).
57. Masters C, Crane D. On the role of the peroxisome in ontogeny, aging and degenerative disease. Mech Ageing Dev 80:69-83 (1995).
58. Soliman M, Cunningnam M, Morrow J, Roberts J, Badr M. Evidence against peroxisome proliferation-induced hepatic oxidative damage: levels of esterified isoprostanes in livers of mice fed a diet containing [4-chloro-6[2,3-xylidino]-2-pyrimidinylthio] acetic acid (WY-14,643). Biochem Phamacol 53:1389-1374 (1997).
59. Kraupp-Grasl B, Huber W, Taper H, Schulte-Hermann R. Increased susceptibility of aged rats to hapatocarcinogenesis by the peroxisome proliferator nafenopin end the possible involvement of altered liver foci occurring spontaneously. Cancer Res 51:666-871 (1991).
60. Badr M, Birnbaum L Selective induction of peroxisomal enzyme activities by perfluorooctanoic acid in aged rats [Abstract]. Toxicologist 187:11 (1991).
61. 2-induced hepatic oxidant injury in aged rats [Abstract]. FASEB J 4:A302 (1982).
62. Semsei I, Rao G, Richardson A. Changes in the expression of superoxide dismutase and catalase as a function of age and dietary restriction. Biocham Biophys Res Commun 164:620-625 (1989).
63. Xia E, Rao G, Van Remmen H, Heydari A, Richardson A. Activities of antioxidant enzymes in various tissues of male Fischer 344 rats are altered by food restriction. J Nutr 125:195-201 (1995).
64. Haining JL, Legan JS. Catalase turnover in rat liver and kidney as a function of age. Exp Gerontol 8:85-91 (1973).
65. Yamoto T, Ohashi Y, Teranishi M, Takaoka M, Manaba S, Matsunuma N, Makita T. Age-related changes in the susceptibility to clofibric acid, a hypolipidemic agent, of male rat liver. Toxicol Lett 78:141-145 (1995).
66. Badr M. Unpublished data.
67. Roth GS. Age changes in signal transaction and gene expression. Mech Ageing Dev 98:231-238 (1997).
68. Pallet V, Azais-Braesco V, Enderlin V, Grolier P, Noel-Suberville C, Garcin H, Higueret P. Aging decreases retinoic acid and triiodothyronine nuclear expression in rat liver: exogenous retinol and retinoic acid differentially modulates this decreased expression. Mech Ageing Dev 99:123-136 (1997).
69. O'Brien MLO, Rangwala SM, Henry KW, Weinberger C, Crick DC, Waecher CJ, Feller DR, Noonan DJ. Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis, Carcinogenesis 17:185-190 (1996).
70. Mukherjee R, Strasser J, Jow L, Hoener, P, Psterniti J, Heyman R. RXR agonists activate PPARα-inducible genes, lower triglycerides and raise HDL levels in vivo. Arterioscler Thromb Vasc Biol 18:272-276 (1998).
71. Castelein H, Gulick T, Declercq P, Mannaerts G, Moore D, Baas M. The peroxisome proliferator activated receptor regulates malic enzyme gene expression. J Biol Chem 269:26754-28758 (1994).
72. Miller R, Glover S, Stewart W, Corton J, Popp J, Cattley R. Effect on the expression of c-met, c-myc and PPARα in liver end liver tumors from rats chronically exposed to the hepatocarcinogenic peroxisome proliferator WY-14,643. Carcinogenesis 17:1337-1341 (1996).
73. Schutgens R, Heyman H, Wanders R, Vandenbosch H, Tager J. Peroxisomal disorders: a newly recognized group of genetic diseases. Eur J Pediatr 144:430-440 (1986).
74. Singh I. Biochemistry of peroxisomes in health and disease. Mol Cell Biochem 167:1-29 (1997).
75. Xu L, Ash M, Abdel-aleem S, Lowe J, Badr M. Hyperinsulinemia inhibits hepatic peroxisomal β-oxidation in rats. Horm Metab Res 27:76-78 (1995).
76. Shimozawa N, Suzuki Y, Zhang Z, Imamura A, Tsukamoto T, Osumi T, Tateishi K, Okumoto K, Fujiki Y, Orii T, et al. Peroxisome biogenesis disorders: identification of a new complementation group distinct from peroxisome-deficient CHO mutants and not complemented by human PEX 13. Biochem Biophys Res Commun 243:388-371 (1998).
77. Moser AE, Rasmussen M, Naidu S, Watkins P, McGuinness M, Hajra AK, Chen 6, Raymond G, Liu A, Gordon D, et al. Phenotype of patients with peroxisomal disorders subdivided into 16 complimentation groups. J Pediatr 127:13-22 (1995).
78. Goldfischer S, Moore CL, Johnson AB, Spiro AJ, Valsamis MP, Wisnieski HK, Ritch RH, Norton WT, Rapin I, Gartner LM. Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. Science 182:62-84 (1973).
79. Singh I, Moser AE, Goldfischer S, Moser HW. Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci USA 81:4203-4207 (1964).
80. Singh I, Lazo O, Contreras M, Stanley W, Hashimoto T. Rhizomelic chondrodysplasia punctate: biochemical studies of peroxisomes isolated from cultured skin fibroblasts. Arch Biochem Biophys 266:277-283 (1991).
81. Roberts R, James N, Woodyatt N, Macdonald N, Tugwood J. Evidence for the suppression of epoptosis by the peroxisome proliferator activated receptor alpha (PPARα). Carcinogenesis 19:43-48 (1998).
82. Bayly A, Roberts R, Dive C. Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin. J Cell Biol 125:197-203 (1994).
83. Ellis R, Yuan J, Horvitz H. Mechanisms and functions of cell death. Annu Rev Cell Biol 7:663-689 (1991).
84. Roberts R, Soames A, Gill J, James N, Wheeldon E. Nongenotoxic hepatocarcinogens stimulate DMA synthesis and their withdrawal induces apoptosis but in different hepatocyte populations. Carcinogenesis 18:1893-1898 (1995).
85. Warner H. Aging and regulation of apoptosis. Curr Top Cell Regul 35:107-121 (1997).
86. Xin X, Yeng S, Kowalski J, Gerritsen M. Peroxisome proliferetor-activated receptor gamma (PPARγ) ligands are potent inhibitors of angiogenesis. FASEB J 13:A39 (1999).
87. Kliewer S, Sundseth S, Jones S, Brown P, Wisely GB, Koble C, Devchand P, Wahli W, Wilson T, Lenhard J, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 94:4318-4323 (1997).
88. Zs-Nagy I. The role of membrane structure and function in cellular aging: a review. Mech Ageing Dev 9:237-246 (1979).
89. Roth G, Joseph J, Mason R. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci 18:203-206 (1995).
90. Stubbs C, Smith A. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophs Acta 779:89-137 (1984).
91. Jakobs B, Wanders R. Conclusive evidence that very long chain fatty acids are oxidized exclusively in peroxisomes in human skin fibroblasts. Biochem Biophs Res Commun 178:842-847 (1991).
92. Takai Y, Kikkawa U, Kaibuchi K, Nishizuka Y. Membrane phospholipid metabolism and signal transduction for protein phosphorylation. Adv Cyclic Nucleotide Protein Phosphorylation Res 18:119-158 (1984).
93. Hey MJ, Clough MJ, Taylor DJ. Ion effects on macromolecules in aqueous solution. Nature 262:807-809 (1976).
94. Cone CD. Unified theory on the basic mechanism of normal mitotic control and oncogenesis. J Theor Biol 30:151-181 (1971).
95. Fausto N, Laird AD, Webber EM. Role of growth factors and cytokines in hepatic regeneration. FASEB J 9:1527-1538 (1995).
96. Diehl AM, Rai RM. Regulation of signal transduction during liver regeneration. FASEB J 10:215-227 (1996).